Company: RNAC
Filing Date: 2025-01-08
Form Type: 424B7
Source: 0001140361-25-000634
Chunk: 4

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-01-08
Form: 424B7
Chunk 4
---
 to, the following:

| • | our ability to achieve the expected benefits or opportunities and related timing with respect to the Merger (as defined below) or to monetize any of our legacy assets; |

| • | our future results of operations and financial position, business strategy, and the length of time that we believe our existing cash resources will fund our operations; |

| • | our market size and our potential growth opportunities; |

| • | our preclinical and clinical development activities; |

| • | the efficacy and safety profile of our product candidates; |

| • | the potential therapeutic benefits and economic value of our product candidates; |

| • | the timing and results of preclinical studies and clinical trials; |

| • | the expected impact of macroeconomic conditions, including inflation, increasing interest rates and volatile market conditions, current or potential bank failures; |

| • | global events, including the ongoing conflicts between Russia and Ukraine and between Hamas and Israel and geopolitical tensions in China on our operations; |

| • | the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates; |

| • | potential litigation related to the Merger instituted against us or our directors; |

| • | our ability to prevent or minimize the effects of litigation and other contingencies; |

| • | our status as a preclinical and development-stage company and our expectation to incur losses in the future, and the possibility that we never achieve or maintain profitability; |

| • | uncertainties with respect to our ability to access future capital; |

| • | our ability to maximize the value of our pipeline of product candidates; |

| • | our unproven approach to therapeutic intervention; |

| • | our ability to enroll patients in clinical trials, timely and successfully complete those trials and receive necessary regulatory approvals; |

2

TABLE OF CONTENTS

| • | our ability to continue to grow our manufacturing capabilities and resources; |

| • | our ability to manufacture our product candidates, which in some cases are manufactured on a patient-by-patient basis; |

| • | our ability to access manufacturing facilities and to receive or manufacture sufficient quantities of our product candidates; |

| • | our ability to maintain our existing or future collaborations or licenses and to seek new collaborations, licenses or partnerships; |

| • | the impact of resurgence of the COVID-19 pandemic on our operations, the continuity of our business, including our preclinical studies and clinical trials, and general economic conditions; |

| • | our ability to protect and enforce our